Lloyd Carney - 30 Jan 2023 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role
Director
Signature
/s/ Christiana Stevenson, Attorney-in-Fact
Issuer symbol
VRTX
Transactions as of
30 Jan 2023
Net transactions value
-$865,406
Form type
4
Filing time
31 Jan 2023, 15:45:28 UTC
Previous filing
26 Jan 2023
Next filing
01 May 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Sale $440,430 -1,376 -20% $320.08 5,474 30 Jan 2023 Direct F1, F2, F3
transaction VRTX Common Stock Sale $320,700 -1,000 -18% $320.70 4,474 30 Jan 2023 Direct F1, F2, F4
transaction VRTX Common Stock Sale $104,276 -324 -7.2% $321.84 4,150 30 Jan 2023 Direct F1, F2, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction made pursuant to Mr. Carney's company approved trading plan under Rule 10b5-1.
F2 Mr. Carney undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F3 Open market sales reported on this line occurred at a weighted average price of $320.08 (range $319.40 to $320.38).
F4 Open market sales reported on this line occurred at a weighted average price of $320.70 (range $320.43 to $321.31).
F5 Open market sales reported on this line occurred at a weighted average price of $321.84 (range $321.54 to $322.23).